S-1: Flora Growth Pivots to AI & Crypto, Secures $50M ELOC

Flora Growth Corp., soon to be ZeroStack, is undergoing a major strategic shift towards AI infrastructure and digital assets, backed by significant private placements and a new $50 million equity line of credit.

Summary

• Flora Growth Corp. is rebranding to ZeroStack and shifting its core business strategy to focus on AI infrastructure through strategic ownership in 0G Tokens, which participate in a decentralized AI network.
• The company will continue to operate its global pharmaceutical distribution business through its wholly-owned German subsidiary, Phatebo, which distributes a wide range of pharmaceutical goods across 28 countries.
• Flora Growth recently divested its legacy hemp and cannabis business on September 26, 2025, in exchange for the full repayment of US$2,222,143 in promissory notes.
• A 1-for-39 reverse stock split was effected on August 4, 2025, with common shares trading on a post-consolidation basis on Nasdaq under the symbol FLGC.
• The company completed several private placements in 2025, raising substantial capital and acquiring significant digital assets:
• May 2025 Private Placement: US$1.1 million net proceeds, used to purchase Solana ($0.4M), Ethereum ($0.4M), Sui ($0.1M), Ripple ($0.1M), and for general corporate purposes.
• Cash Private Placement (September 2025): US$13.66 million net proceeds, used for digital asset treasury strategy (0G) and general corporate purposes. CEO Daniel Reis-Faria exchanged 50,000,000 0G Tokens (valued at US$150 million) for 5,954,743 pre-funded warrants.
• Token Private Placement (September 2025): US$215.3 million net proceeds (from 71,766,135 Tokens valued at US$3.00 each), used for digital asset treasury strategy (0G) and general corporate purposes.
• Note Private Placement (September 2025): Issued a convertible note for Solana with a current value of US$22.88 million, accruing 8% interest, convertible into common shares at US$33.34/share after shareholder approval.
• Zero Gravity Private Placement (September 2025): Issued a convertible note for 50,000,000 0G Tokens with a current value of US$150 million, accruing 8% interest, convertible into common shares at US$33.34/share after shareholder approval.
• An Equity Line of Credit (ELOC) agreement was entered into with White Lion Capital LLC on November 28, 2025, allowing Flora Growth to sell up to $25 million (potentially $50 million) of common shares to White Lion over 24 months.
• The proceeds from the ELOC, if utilized, are intended to be used 80% for the acquisition of 0G Tokens and 20% for general corporate purposes.
• As of November 28, 2025, the company had 746,810 common shares issued and outstanding, with a last reported per share sale price of $8.00 on Nasdaq on November 26, 2025.
• The company is an 'emerging growth company' and 'smaller reporting company', electing to comply with reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The filing outlines a bold strategic pivot with significant capital raises, which could be seen as positive for growth potential. However, the substantial dilution, high volatility and regulatory uncertainty of the cryptocurrency market, and potential conflicts of interest introduce considerable risks, leading to a neutral-to-slightly positive sentiment.

Positives

• Successfully raised significant capital through multiple private placements, totaling over US$380 million in cash and digital assets, providing substantial liquidity for its new strategic direction.
• Strategic pivot towards AI infrastructure and digital assets (0G Tokens) positions the company in high-growth, innovative sectors.
• Maintains a stable revenue stream through its established global pharmaceutical distribution subsidiary, Phatebo, operating in 28 countries.
• Divestment of the legacy hemp and cannabis business streamlines operations and eliminates associated debt of US$2,222,143, allowing for greater focus on the new core pillars.
• Secured an additional $25 million (potentially $50 million) through an Equity Line of Credit (ELOC) with White Lion Capital LLC, providing a flexible funding source for future growth and digital asset acquisitions.

Negatives

• The ELOC agreement and recent private placements will cause substantial dilution to existing shareholders, with the 6,300,000 shares offered for resale by White Lion representing approximately 89.40% of current outstanding common shares.
• The company's financial results and stock price are expected to be highly volatile due to its significant holdings in cryptocurrencies (0G, Solana, Ethereum, Sui, Ripple), which are inherently volatile assets.
• Regulatory uncertainty surrounding digital assets and their classification as 'securities' poses a significant risk, potentially leading to increased regulatory restrictions, enforcement actions, fines, or even requiring the company to register as an investment company.
• The concentration of 0G holdings limits risk mitigation compared to a diversified portfolio, magnifying the impact of any significant decline in 0G price.
• New executive officers (CEO Daniel Reis-Faria and Executive Chairman Michael Heinrich) have limited prior experience as executive officers of publicly traded companies, which could lead to integration difficulties or loss of investor confidence.
• Potential conflicts of interest exist due to executive officers' and directors' involvement with related parties, such as Michael Heinrich being CEO of 0G Labs (native token is 0G) and Daniel Reis-Faria's involvement with DeFi Development Corp. (Note Investor).

Risks

• Limited operating history and net losses.
• Fluctuations in the market price of 0G Tokens or any other digital assets held.
• The possibility that 0G Tokens, Solana, or other digital assets may be classified as a 'security', leading to additional regulatory restrictions.
• Decrease in liquidity of 0G Tokens or any other digital assets held.
• Ability to continue as a going concern absent access to sources of liquidity.
• Damage to reputation as a result of negative publicity.
• Exposure to product liability claims, actions, and litigation.
• Risks associated with product recalls.
• Continuing research and development efforts to respond to technological and regulatory changes.
• Ability to successfully integrate businesses that are acquired.
• Ability to achieve economies of scale.
• Ability to fund overhead expenses, including costs associated with being a publicly-listed company.
• Maintenance of effective quality control systems.
• Changes to energy prices and supply.
• Risks associated with expansion into new jurisdictions.
• Regulatory compliance risks.
• Potential delisting resulting in reduced liquidity of common shares.
• Inability to predict the actual number of shares sold under the ELOC Agreement, gross proceeds, or dilution.
• Inability to access a part or all of the amount available under the ELOC Agreement could have a material adverse effect.
• Investors buying shares from the Selling Shareholder at different times will likely pay different prices and experience different levels of dilution.
• Future sales by the company to the Selling Shareholder at lower prices could cause a decline in the value of shares purchased by investors.
• The company may use proceeds from ELOC sales in ways investors may not agree with or that may not yield significant returns.
• The company may be a 'passive foreign investment company' (PFIC) for tax purposes, which could have adverse U.S. federal income tax consequences for U.S. investors.
• Regulatory developments related to crypto assets and crypto asset markets could adversely affect the business.
• 0G is a highly volatile asset, and price fluctuations may influence financial results and common share price.
• The acquisition of large amounts of 0G may become difficult or more costly.
• Historical financial statements do not reflect the potential variability in earnings from 0G holdings due to fair value accounting.
• Concentration of 0G holdings magnifies risks inherent in the 0G treasury strategy.
• If the network of any cryptocurrencies is disrupted or encounters unanticipated difficulties, the value could be negatively impacted.
• Risks relating to the custody of cryptocurrencies, including loss or destruction of private keys, cyberattacks, or smart contract vulnerabilities.
• The 0G treasury strategy subjects the company to enhanced regulatory oversight, including anti-money laundering and sanctions laws.
• Competition from the emergence or growth of other digital assets could negatively impact the price of 0G.
• 0G holdings will be less liquid than cash and cash equivalents and may not serve as a source of liquidity to the same extent.
• Many countries and regulatory authorities may implement regulations on AI that the 0G Blockchain may be unable to comply with.
• Risks relating to the sale of the legacy hemp and cannabis business, including indemnification claims or failure to achieve anticipated benefits.
• Difficulties due to changes in management, including new executive officers' limited public company experience and potential conflicts of interest.

Future Outlook

The company intends to aggressively pursue its new digital asset treasury strategy, focusing on accumulating 0G Tokens for the long-term and exploring the native AI functionality of the 0G Token to enhance its business. It plans to monitor regulatory developments in cryptocurrencies and may modify its strategy to ensure compliance. The company also expects to continue its pharmaceutical distribution business through Phatebo. Future capital raising transactions collateralized by cryptocurrency holdings and strategies to create income streams from these holdings are also contemplated.

Management Comments

• Our Board and senior management have been examining potential uses of cash, including acquisitions of cryptocurrency. After studying various alternatives, we decided that investing in cryptocurrency is currently a better business strategy.
• We intend to hold 0G for the long-term and expect to continue to accumulate 0G.
• We intend to monitor ongoing developments in the regulatory environment around cryptocurrencies, including pending federal legislation, and may modify or expand our treasury strategy to the extent we determine compliant with federal rules and regulations.
• As we embark on our new acquisition strategy, our Board intends to proactively evaluate our use of cash, ensuring we maintain adequate working capital.

Industry Context

Flora Growth's strategic pivot to AI infrastructure and digital assets places it in a rapidly evolving and highly competitive 'cryptoeconomy' that is attracting significant investment and regulatory scrutiny. This move aligns with broader tech trends of decentralization and AI integration, but also exposes the company to the inherent volatility and regulatory uncertainties of the crypto market. Its continued operation in pharmaceutical distribution provides a more traditional, regulated business segment, offering some diversification from the high-risk digital asset strategy. The company's focus on 0G Tokens, linked to a layer-1 blockchain for decentralized AI, positions it within a niche but potentially high-growth area of the blockchain space, competing with other smart contract platforms like Ethereum and Solana.

Comparison to Industry Standards

• The company's strategy of holding a significant portion of its treasury in cryptocurrencies like 0G and Solana is comparable to a limited number of other publicly traded companies, such as MicroStrategy (MSTR) with its substantial Bitcoin holdings, or certain blockchain-focused investment vehicles. However, Flora Growth's specific focus on 0G Tokens, which are newly minted and tied to AI infrastructure, represents a more specialized and potentially higher-risk approach compared to holding more established digital assets like Bitcoin or Ethereum.
• The pharmaceutical distribution business through Phatebo operates in a mature and regulated industry, with its focus on 28 countries, primarily in Europe, aligning with standard international distribution models. No specific comparable companies or projects are detailed in the filing to assess its performance against industry benchmarks.

Management Changes

Corporate Governance

Related Party Transactions

• Daniel Reis-Faria, the Chief Executive Officer, received 5,954,743 Cash Pre-funded Warrants in exchange for contributing 50,000,000 0G Tokens (valued at approximately US$150 million) to the company as part of the Cash Private Placement.
• Michael Heinrich, the Executive Chairman, is also the Chief Executive Officer of 0G Labs, the entity whose native cryptocurrency is the 0G Token, which Flora Growth Corp. is strategically accumulating.
• Daniel Reis-Faria originated and facilitated the investment transaction between Janover and DeFi Development Corporation, which led to the creation of the first Solana Treasury Vehicle in the United States. Mr. Reis-Faria is a shareholder of DeFi Development Corporation, which is the Note Investor in the US$22.88 million Note Private Placement.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the issuance of shares under the ELOC and the conversion of warrants/notes from private placements. The value of their holdings will be highly sensitive to the volatile cryptocurrency market and the success of the new AI infrastructure strategy.
• Employees: The strategic shift and divestment of the legacy business may lead to changes in workforce focus and skill requirements, though the filing notes 21 full-time employees across North America and Germany.
• Customers (Phatebo): The pharmaceutical distribution business is expected to continue, implying stable service for existing customers.
• Creditors: The repayment of US$2.22 million in promissory notes through the legacy business disposition is positive for creditors. The new convertible notes introduce new debt obligations, albeit denominated in digital assets.

Next Steps

• The registration statement must become effective with the SEC before the company can commence sales of shares to White Lion under the ELOC Agreement.
• Shareholder approval is required for the conversion of the Note and Zero Gravity Convertible Note into common shares, and potentially for issuing shares in excess of the Nasdaq Exchange Cap under the ELOC Agreement.
• The company plans to file a re-sale registration statement on Form S-3 for the Cash Common Shares, Cash Pre-funded Warrant Shares, and Cash Warrant Shares no later than six months after shareholder approval.
• The company intends to establish and formally adopt a digital assets treasury policy, to be approved by the Board and reviewed quarterly.
• The company will continue to monitor market conditions to determine whether to engage in further financings to purchase additional cryptocurrency.
• The company will continue to explore and expand the use of the native AI functionality of the 0G Token to enhance its business.

Key Dates

Recommendation

Flora Growth Corp. is undergoing a transformative strategic pivot into the highly speculative and volatile digital asset and AI infrastructure space, while divesting its traditional cannabis business. The company has secured substantial capital through private placements and an ELOC, which provides liquidity for its new direction. However, this comes with significant shareholder dilution, and the inherent risks of cryptocurrency price volatility, evolving regulatory landscape, and potential conflicts of interest due to management's ties to 0G Labs are substantial. The pharmaceutical distribution segment offers some stability but is overshadowed by the new, high-risk strategy. Given the early stage of this pivot and the extreme uncertainty in the crypto market, a 'hold' recommendation is appropriate for investors to observe the execution of the new strategy and the market's reaction to its digital asset holdings and AI initiatives, while acknowledging both the high-reward potential and significant downside risks.

Keywords

AI infrastructure, 0G Tokens, Cryptocurrency, Digital Assets, Equity Line of Credit, ELOC, Private Placement, Solana, Ethereum, Phatebo, Pharmaceutical Distribution, ZeroStack, FLGC, SEC Filing, Dilution, Corporate Strategy